The U.S. Food and Drug Administration (FDA) has cleared GE Healthcare’s SenoBright contrast enhanced spectral mammography (CESM) unit, the company announced on Thursday. The technology is designed to produce contrast-enhanced images of the breast using an x-ray contrast agent and a dual energy acquisition technique.
The U.S. Food and Drug Administration (FDA) has cleared GE Healthcare’s SenoBright contrast enhanced spectral mammography (CESM) unit, the company announced on Thursday.
The technology is designed to produce contrast-enhanced images of the breast using an X-ray contrast agent and a dual energy acquisition technique. SenoBright uses X-rays at multiple energies to create two separate but almost simultaneous exposures. The resulting images illuminate and highlight areas of iodinated contrast. SenoBright is already in use at 17 major mammography centers in France, Spain, Italy, Belgium, Germany, Austria, and Japan, GE said.
“CESM presents two images per mammographic view, one that looks like standard mammography and a second image that shows the contrast enhanced areas that can help localize a lesion. As the images are familiar, it can therefore be easily reviewed by surgeons and oncologists. Moreover in terms of workflow, a CESM exam takes from five to 10 minutes,” said Dr. Clarisse Dromain, Gustave Roussy Cancer Institute, France.
SenoBright is intended to allow for a procedure to be conducted by the same staff, using the same mammography equipment, potentially on the same day as a traditional screening exam, thereby helping medical professionals to cut the critical time patients often have to wait from detection to diagnosis, the company said. GE said the 2,500 Senographe DS and Senographe Essential digital mammography systems in use today are upgradeable to SenoBright.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 1st 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
August 1st 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
Twenty Years of CT Colonography for Colorectal Cancer Screening: What the Research Reveals
August 1st 2025Computed tomography colonography (CTC) demonstrated a 91.6 percent positive predictive value (PPV) for polyps > 6 mm, according to new research involving over 9,000 patients who underwent CTC for primary asymptomatic colorectal cancer screening.